{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Neuroendocrine&page=2", "query": { "condition": "Carcinoma, Neuroendocrine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Neuroendocrine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:28:44.102Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04869137", "title": "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Neuroendocrine Carcinoma of the Skin", "Trabecular Carcinoma of the Skin" ], "interventions": [ { "name": "Lenvatinib Oral Product", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-05-28", "completion_date": "2026-09", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04869137" }, { "nct_id": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Gastric Cancer", "Esophageal Cancer", "Pancreas Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Colo-rectal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "ADCT-301", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2018-11-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03621982" }, { "nct_id": "NCT02507076", "title": "Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Basal Cell Carcinoma of the Skin", "Eccrine Carcinoma of the Skin", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Melanoma", "Recurrent Skin Cancer", "Squamous Cell Carcinoma of the Skin", "Stage III Adult Soft Tissue Sarcoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Melanoma" ], "interventions": [ { "name": "isolated limb perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-07-23", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02507076" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT00923247", "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Medullary Thyroid Carcinoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2009-02-19", "completion_date": "2016-12-09", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923247" }, { "nct_id": "NCT00092287", "title": "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Carcinoid Syndrome" ], "interventions": [ { "name": "lanreotide Autogel (somatostatin analogue)", "type": "DRUG" }, { "name": "Sandostatin long acting release (LAR) Depot (somatostatin analogue)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2004-07", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2020-04-30", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092287" }, { "nct_id": "NCT03075072", "title": "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Whole brain radiation", "type": "RADIATION" }, { "name": "Stereotactic radiation (SRS)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 196, "start_date": "2017-04-10", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075072" }, { "nct_id": "NCT01273181", "title": "MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Renal Cancer", "Metastatic Melanoma" ], "interventions": [ { "name": "PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2010-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273181" }, { "nct_id": "NCT00418496", "title": "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-11-08", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00418496" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-05-21T23:28:44.102Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" } ] }